BOUCHERVILLE, QC, Oct. 21, 2026 /CNW/ -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced that Research Capital Corporation has initiated equity research coverage of LSL Pharma. Research Capital is the first independent equity research group to publish an analyst coverage report on LSL Pharma.
Research Capital's initial report on LSL Pharma (the "Research Report") was authored by Andre Uddin, Ph.D. LSL Pharma does not distribute analyst reports to persons outside of the Corporation. Please contact a Research Capital Corp investment advisor directly to obtain a copy of the report.
Any opinions, estimates or forecasts expressed in the Research Report are those of Research Capital. Such opinions, estimates and forecasts have not received any endorsement or approval by the Corporation. As such, the Corporation does not imply or in any way represent that the Research Report or any of the opinions, estimates or forecasts expressed therein represent the opinions or beliefs of the Corporation or its management. The Corporation has not paid Research Capital any fee in connection with this coverage and is not responsible for the content, accuracy or timeliness of the Research Report.
About LSL Pharma Group Inc.
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities, and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly-owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and LSL MedPlus Inc. (formerly Juno OTC Inc.) For more information, please visit our website at at www.groupelslpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward looking statements include estimates and statements that describe the Corporation's future plans, objectives or goals, including words to the effect that the Corporation or management expects a stated condition, belief, estimate or opinion, or result to occur. Forward-looking statements may be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "believe", "aim", "plan" "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, potential changes in market conditions.
Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Groupe LSL PHARMA INC.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2026/21/c7876.html
François Roberge, President and Chief Executive Officer, (514) 664-7700, E-mail: Investors@groupelslpharma.com